Tuesday, February 07, 2017 10:03:22 PM
CT ORDER -- Documents -- Confidential treatment order
Acc-no: 9999999997-17-000586 (34 Act) Size: 11 KB 2017-02-06 000-55136 17576344
You can find it here:
https://www.sec.gov/Archives/edgar/data/1516551/999999999717000586/filename1.pdf
Inside the confidential treatment order it refers to the 8K filing on 1/13/2017 which you can find below and the pdf further states that "Nemus Bioscience, Inc. submitted an application under Rule 24b-2 REQUESTING CONFIDENTIAL TREATMENT FOR INFORMATION IT EXCLUDED FROM THE EXHIBIT to a Form 8-K filed on
January 13, 2017.... through January 10, 2027" (FOR THE NEXT TEN YEARS) which means they have really obtained something very substantial to the point the can have it excluded from disclosing. That, my friends, is very rare.
Here is the 8K filing it was excluded from:
https://www.sec.gov/Archives/edgar/data/1516551/000164033417000091/nmus_8k.htm
On January 10, 2017, Nemus Bioscience, Inc. (the “Company”) entered into a license agreement (the “License Agreement”) with the University of Mississippi, School of Pharmacy (“UM”), pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, under intellectual property related to UM5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases. The License Agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like methicillin-resistant Staphylococcus aureus (MRSA). (So it must really be something special to exclude it for ten years and apparently more important that this MRSA therapy they DID disclose.)
It's definitely a good thing. Truly a case of when no news is good news /2017)! (This,thanks to Gee, yahoo conversation board)!
Recent SKYE News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2024 04:15:09 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/17/2024 08:27:44 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:19:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:02:13 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM